Cinryze is a human plasma-derived C1 Esterase Inhibitor indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and adolescent patients

**Pre-Authorization:**

VCHCP will authorize Cinryze for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and adolescent patients

**Dosing (adult and adolescent):**

- **Prophylaxis:** 1000 units IV every 3-4 days
- **Acute episodes:** 20 units/kg IV

**PRECAUTIONS:** headache/dizziness; nausea/vomiting; rash/pruritis; flu-like symptoms; injection site irritation; hypersensitivity/anaphylaxis (rare)

**DRUG INTERACTIONS:** There are currently no known significant interactions.

**REFERENCES**


**Revision History:**

- Date Approved by P&T Committee: 10/22/13
- Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
- Date Approved by P&T Committee: 1/28/14
- Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
- Date Approved by P&T Committee: 1/27/15
- Date Reviewed/Updated: 2/17/15 by C. Sanders, MD; R. Sterling, MD
- Date Approved by P&T Committee: 1/26/16
- Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
- Date Approved by P&T Committee: 1/24/17
- Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
- Date Approved by P&T Committee: 1/23/18
- Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
- Date Approved by P&T Committee: 1/22/19

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>